Seroincidence of SARS-CoV-2 infection prior to and during the rollout of vaccines in a community-based prospective cohort of U.S. adults
© 2024. The Author(s)..
This study used repeat serologic testing to estimate infection rates and risk factors in two overlapping cohorts of SARS-CoV-2 N protein seronegative U.S. adults. One mostly unvaccinated sub-cohort was tracked from April 2020 to March 2021 (pre-vaccine/wild-type era, n = 3421), and the other, mostly vaccinated cohort, from March 2021 to June 2022 (vaccine/variant era, n = 2735). Vaccine uptake was 0.53% and 91.3% in the pre-vaccine and vaccine/variant cohorts, respectively. Corresponding seroconversion rates were 9.6 and 25.7 per 100 person-years. In both cohorts, sociodemographic and epidemiologic risk factors for infection were similar, though new risk factors emerged in the vaccine/variant era, such as having a child in the household. Despite higher incidence rates in the vaccine/variant cohort, vaccine boosters, masking, and social distancing were associated with substantially reduced infection risk, even through major variant surges.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Scientific reports - 14(2024), 1 vom: 05. Jan., Seite 644 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nash, Denis [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 08.01.2024 Date Revised 15.01.2024 published: Electronic UpdateOf: medRxiv. 2023 Oct 02;:. - PMID 37873066 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41598-023-51029-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366733478 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366733478 | ||
| 003 | DE-627 | ||
| 005 | 20240115232020.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-023-51029-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1260.xml |
| 035 | |a (DE-627)NLM366733478 | ||
| 035 | |a (NLM)38182731 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nash, Denis |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Seroincidence of SARS-CoV-2 infection prior to and during the rollout of vaccines in a community-based prospective cohort of U.S. adults |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.01.2024 | ||
| 500 | |a Date Revised 15.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateOf: medRxiv. 2023 Oct 02;:. - PMID 37873066 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a This study used repeat serologic testing to estimate infection rates and risk factors in two overlapping cohorts of SARS-CoV-2 N protein seronegative U.S. adults. One mostly unvaccinated sub-cohort was tracked from April 2020 to March 2021 (pre-vaccine/wild-type era, n = 3421), and the other, mostly vaccinated cohort, from March 2021 to June 2022 (vaccine/variant era, n = 2735). Vaccine uptake was 0.53% and 91.3% in the pre-vaccine and vaccine/variant cohorts, respectively. Corresponding seroconversion rates were 9.6 and 25.7 per 100 person-years. In both cohorts, sociodemographic and epidemiologic risk factors for infection were similar, though new risk factors emerged in the vaccine/variant era, such as having a child in the household. Despite higher incidence rates in the vaccine/variant cohort, vaccine boosters, masking, and social distancing were associated with substantially reduced infection risk, even through major variant surges | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 700 | 1 | |a Srivastava, Avantika |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Yanhan |e verfasserin |4 aut | |
| 700 | 1 | |a Penrose, Kate |e verfasserin |4 aut | |
| 700 | 1 | |a Kulkarni, Sarah G |e verfasserin |4 aut | |
| 700 | 1 | |a Zimba, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a You, William |e verfasserin |4 aut | |
| 700 | 1 | |a Berry, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Mirzayi, Chloe |e verfasserin |4 aut | |
| 700 | 1 | |a Maroko, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Parcesepe, Angela M |e verfasserin |4 aut | |
| 700 | 1 | |a Grov, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Robertson, McKaylee M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 14(2024), 1 vom: 05. Jan., Seite 644 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:1 |g day:05 |g month:01 |g pages:644 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-023-51029-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 1 |b 05 |c 01 |h 644 | ||